{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:03:40Z","timestamp":1793325820162,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"\n Importance<\/jats:title>\n Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce aldosterone synthesis may lower blood pressure.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] \u22641.0 ng\/mL\/h) and elevated plasma aldosterone (\u22651.0 ng\/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng\/mL\/h.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to placebo or 1 of 5 dosages of lorundrostat in the initial cohort (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily). In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was change in automated office systolic blood pressure from baseline to study week 8.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022. Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of \u221214.1, \u221213.2, \u22126.9, and \u22124.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were \u221210.1 and \u221213.8 mm Hg, respectively. The least-squares mean difference between placebo and treatment in systolic blood pressure was \u22129.6 mm Hg (90% CI, \u221215.8 to \u22123.4 mm Hg;\n P<\/jats:italic>\n \u2009=\u2009.01) for the 50-mg once-daily dose and \u22127.8 mm Hg (90% CI, \u221214.1 to \u22121.5 mm Hg;\n P<\/jats:italic>\n \u2009=\u2009.04) for 100 mg daily. Among participants without suppressed PRA, 100 mg once daily of lorundrostat decreased systolic blood pressure by 11.4 mm Hg (SD, 2.5 mm Hg), which was similar to blood pressure reduction among participants with suppressed PRA receiving the same dose. Six participants had increases in serum potassium above 6.0 mmol\/L that corrected with dose reduction or drug discontinuation. No instances of cortisol insufficiency occurred.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05001945<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.16029","type":"journal-article","created":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:30:42Z","timestamp":1694334642000},"page":"1140","source":"Crossref","is-referenced-by-count":215,"title":["Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension"],"prefix":"10.1001","volume":"330","author":[{"given":"Luke J.","family":"Laffin","sequence":"first","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"C5 Research, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodman","sequence":"additional","affiliation":[{"name":"Mineralys Therapeutics, Radnor, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Luther","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Rajicic","sequence":"additional","affiliation":[{"name":"Cytel, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. T.","family":"Slingsby","sequence":"additional","affiliation":[{"name":"Mineralys Therapeutics, Radnor, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"C5 Research, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Target-HTN Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beasley","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Budoff","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Carr","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carroll","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cevallos Yepez","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Chhabra","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cole","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Dunn","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Eaves","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Ebuh","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Estevez","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Gould","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hong","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Iteld","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra","family":"Jain","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kemp","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kennelly","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kleiner","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kutner","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Laffin","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lambert","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Ledesma","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keung","family":"Lee","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lentz","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lupovitch","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00a0James","family":"Luther","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon","family":"Lynn","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obadias","family":"Marquez","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen","family":"Mazhar","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morin","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Neutel","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaa","family":"Oppong","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin","family":"Osorio","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Patron","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Pharr","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Ponce de Leon","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Rodriguez-Ables","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rosen","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issac","family":"Sachmechi","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Surowitz","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larkin","family":"Wadsworth","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wayne","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Zafar","sequence":"additional","affiliation":[{"name":"for the Target-HTN Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"25","key":"joi230099r1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health.","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"joi230099r2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018.","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"joi230099r3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association.","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"joi230099r4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/hr.2017.75","article-title":"The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins.","volume":"40","author":"Leggio","year":"2017","journal-title":"Hypertens Res"},{"issue":"1","key":"joi230099r5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"the unrecognized prevalence of primary aldosteronism: a cross-sectional study.","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"joi230099r6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.121.18761","article-title":"Primary aldosteronism: where are we now? where to from here?","volume":"79","author":"Funder","year":"2022","journal-title":"Hypertension"},{"issue":"4","key":"joi230099r7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ajh\/hpw003","article-title":"The role of aldosterone in obesity-related hypertension.","volume":"29","author":"Kawarazaki","year":"2016","journal-title":"Am J Hypertens"},{"key":"joi230099r8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1016804","article-title":"Association of objective and subjective parameters of obstructive sleep apnea with plasma aldosterone concentration in 2,066 hypertensive and 25,368 general population.","volume":"13","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"joi230099r9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/jhh.2011.47","article-title":"Resistant hypertension, obstructive sleep apnoea and aldosterone.","volume":"26","author":"Dudenbostel","year":"2012","journal-title":"J Hum Hypertens"},{"issue":"4","key":"joi230099r10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5664\/jcsm.27878","article-title":"Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.","volume":"6","author":"Gonzaga","year":"2010","journal-title":"J Clin Sleep Med"},{"issue":"10","key":"joi230099r11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/ajh\/hpac091","article-title":"Relationship between risks for obstructive sleep apnea, resistant hypertension, and aldosterone among African American adults in the Jackson Heart Study.","volume":"35","author":"Koo","year":"2022","journal-title":"Am J Hypertens"},{"issue":"5","key":"joi230099r12","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"12","key":"joi230099r13","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects.","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology"},{"issue":"3","key":"joi230099r14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature.","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"joi230099r15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"15","key":"joi230099r16","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity.","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"joi230099r17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","article-title":"Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice.","volume":"67","author":"Huby","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"joi230099r18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/ijms20051081","article-title":"Genetics of hypertension in African Americans and others of African descent.","volume":"20","author":"Zilbermint","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"joi230099r19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study.","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"joi230099r20","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/HYPERTENSIONAHA.107.109439","article-title":"Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?","volume":"51","author":"Krug","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"joi230099r21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ccl.2010.04.001","article-title":"The role of aldosteronism in causing obesity-related cardiovascular risk.","volume":"28","author":"Calhoun","year":"2010","journal-title":"Cardiol Clin"},{"issue":"10008","key":"joi230099r22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"joi230099r23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension.","volume":"30","author":"Dudenbostel","year":"2017","journal-title":"Am J Hypertens"},{"issue":"5","key":"joi230099r24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors\u2014physiology and pathophysiology.","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"joi230099r25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"joi230099r26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861581","article-title":"Benefits of surgical over medical treatment for unilateral primary aldosteronism.","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"joi230099r27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term.","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"issue":"18","key":"joi230099r28","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"11 Pt 1","key":"joi230099r29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension.","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"issue":"5","key":"joi230099r30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension.","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"joi230099r31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension.","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2809625\/jama_laffin_2023_oi_230099_1695046179.56169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:01:34Z","timestamp":1695726094000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2809625"}},"subtitle":["The Target-HTN Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.16029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742776221.793601364","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}